Business
Directors' Long Term Incentive Scheme
Directors' Long Term Incentive Scheme.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 6213M Futura Medical PLC 18 August 2011 \n \n\n\n\n\n\nFor immediate release\n\n\n18 August 2011\n\n\n\n\n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nDirectors' Long Term Incentive Scheme\nFutura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that the issue of the CE mark for CSD500 on 8 August 2011 will trigger an award of 550,000 Phantom Option Units in accordance with the Company's Long Term Incentive Scheme (\"LTIS\") and as previously disclosed in the Company's annual report. \nFurther details of this award will be given in due course and, in accordance with the LTIS, will be based on the Company's closing share price on the 8 August 2011. The determination will take place as soon as practicable after the release of the Company's interim results for the six months ended 30 June 2011 to be reported on 27 September 2011 and the consequent expiry of the current close period. A further announcement will be made in due course.\nDetails of the LTIS are set out on the Company's website under Governance.\n \n \nFor any further information please contact:\n \n \n\n\n\n\nFutura Medical plc\n\n\n \n\n\n\n\nJames Barder, Chief Executive\n \n\n\nTel: +44 (0)1483 685 670\n\n\n\n\nmail to: [email protected]\n\n\nwww.futuramedical.com\n\n\n\n\n \n\n\n \n\n\n\n\n \nNomura Code Securities Limited\n\n\n \n\n\n\n\nPhil Walker / Giles Balleny\n\n\nTel:+44 (0)20 7776 1200\n\n\n\n\n \n \n\n\n \n\n\n\n\nFor media enquiries please contact:\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nBuchanan Communications\n\n\n \n\n\n\n\nMark Court\n\n\nTel: +44 (0)20 7466 5000\n\n\n\n\n \n \nNotes to Editors\n \nFutura Medical plc\n \nFutura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.\n \nFutura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.\nwww.futuramedical.com \n\nThis information is provided by RNSThe company news service from the London Stock Exchan...